These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 15960286)

  • 21. The management of spasticity in adults.
    Nair KP; Marsden J
    BMJ; 2014 Aug; 349():g4737. PubMed ID: 25096594
    [No Abstract]   [Full Text] [Related]  

  • 22. Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients.
    Elovic EP; Brashear A; Kaelin D; Liu J; Millis SR; Barron R; Turkel C
    Arch Phys Med Rehabil; 2008 May; 89(5):799-806. PubMed ID: 18452724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effectiveness and safety of tolperisone in spasticity following cerebral stroke: randomized, double-blind, placebo-controlled trial].
    Lipták J
    Ideggyogy Sz; 2013 Jul; 66(7-8):283-4. PubMed ID: 23971362
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacokinetic interactions between eperisone hydrochloride and aceclofenac: a randomized, open-label, crossover study of healthy Korean men.
    Kim MJ; Lim HS; Noh YH; Kim YH; Choi HY; Park KM; Kim SE; Bae KS
    Clin Ther; 2013 Oct; 35(10):1528-35. PubMed ID: 24050970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pathogenetic therapy of spasticity].
    Kasatkin DS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(3):80-5. PubMed ID: 18697257
    [No Abstract]   [Full Text] [Related]  

  • 26. Botulinum toxin type A for upper limb spasticity following stroke: an open-label study with individualised, flexible injection regimens.
    Slawek J; Bogucki A; Reclawowicz D
    Neurol Sci; 2005 Apr; 26(1):32-9. PubMed ID: 15877185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human pharmacokinetics of the muscle relaxant, eperisone hydrochloride by liquid chromatography-electrospray tandem mass spectrometry.
    Melilli B; Piazza C; Vitale DC; Marano MR; Pecori A; Mattana P; Volsi VL; Iuculano C; Cardì F; Drago F
    Eur J Drug Metab Pharmacokinet; 2011 Jun; 36(2):71-8. PubMed ID: 21448778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
    Wissel J; Entner T
    Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis.
    Giovannelli M; Borriello G; Castri P; Prosperini L; Pozzilli C
    Clin Rehabil; 2007 Apr; 21(4):331-7. PubMed ID: 17613573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials.
    Yablon SA; Brashear A; Gordon MF; Elovic EP; Turkel CC; Daggett S; Liu J; Brin MF
    Clin Ther; 2007 Apr; 29(4):683-90. PubMed ID: 17617291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response to eperisone in patients of therapy-resistant dissociative convulsions: A report of two cases.
    Jha VN; Singh PK
    Indian J Pharmacol; 2017; 49(1):121-123. PubMed ID: 28458436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transdermal eperisone elicits more potent and longer-lasting muscle relaxation than oral eperisone.
    Yang SI; Park HY; Lee SH; Lee SJ; Han OY; Lim SC; Jang CG; Lee WS; Shin YH; Kim JJ; Lee SY
    Pharmacology; 2004 Jul; 71(3):150-6. PubMed ID: 15161997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Constraint-Induced Movement Therapy After Injection of Botulinum Toxin Type A for a Patient With Chronic Stroke: One-Year Follow-up Case Report.
    Amano S; Takebayashi T; Hanada K; Umeji A; Marumoto K; Furukawa K; Domen K
    Phys Ther; 2015 Jul; 95(7):1039-45. PubMed ID: 25592185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Selection of treatment modalities in patients with spasticity].
    Ota T
    Brain Nerve; 2014 Sep; 66(9):1031-8. PubMed ID: 25200574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of focal upper limb spasticity with botulinum toxin after stroke. Interest of an individual approach].
    Luauté J; Landrault E; Jacquin-Courtois S; Mertens P; Rode G; Boisson D
    Ann Readapt Med Phys; 2004 Oct; 47(8):555-62. PubMed ID: 15465160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical efficacy and safety of eperisone for low back pain: A systematic literature review.
    Bavage S; Durg S; Ali Kareem S; Dhadde SB
    Pharmacol Rep; 2016 Oct; 68(5):903-12. PubMed ID: 27371896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians).
    Bensmail D; Hanschmann A; Wissel J
    J Med Econ; 2014 Sep; 17(9):618-25. PubMed ID: 24841450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum concentration of eperisone hydrochloride correlates with QT interval.
    Yamagiwa T; Morita S; Amino M; Miura N; Saito T; Inokuchi S
    Am J Emerg Med; 2014 Jan; 32(1):75-7. PubMed ID: 24135462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Botulinum toxin for spasticity after stroke.
    Buitrago MM; Koolwijk I
    N Engl J Med; 2003 Jan; 348(3):258-9; author reply 258-9. PubMed ID: 12530438
    [No Abstract]   [Full Text] [Related]  

  • 40. [Acupuncture at tendons node combined with movement for 30 cases of post-stroke spastic paralysis in lower limbs].
    Shi G; Zheng X; Song N
    Zhongguo Zhen Jiu; 2015 Mar; 35(3):212. PubMed ID: 26062181
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.